Celgene Co. (NASDAQ:CELG) – Equities researchers at Leerink Swann issued their FY2018 earnings per share (EPS) estimates for Celgene in a research report issued on Monday, October 15th. Leerink Swann analyst G. Porges expects that the biopharmaceutical company will post earnings of $7.96 per share for the year. Leerink Swann also issued estimates for Celgene’s Q4 2018 earnings at $2.14 EPS, FY2019 earnings at $9.70 EPS, FY2020 earnings at $11.81 EPS, FY2021 earnings at $14.36 EPS and FY2022 earnings at $16.92 EPS.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $2.16 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.05. The business had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.70 billion. Celgene had a net margin of 19.81% and a return on equity of 87.28%. The company’s revenue was up 16.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.82 earnings per share.

A number of other equities analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Celgene from a “buy” rating to a “hold” rating in a research report on Wednesday, September 26th. Mizuho reissued a “buy” rating and issued a $129.00 price objective on shares of Celgene in a research report on Tuesday, July 31st. JPMorgan Chase & Co. reissued a “buy” rating on shares of Celgene in a research report on Thursday, October 11th. Cantor Fitzgerald started coverage on shares of Celgene in a research report on Monday, October 1st. They issued an “overweight” rating and a $100.00 price objective for the company. Finally, BidaskClub lowered shares of Celgene from a “buy” rating to a “hold” rating in a research report on Thursday, September 13th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $119.99.

NASDAQ:CELG opened at $82.95 on Wednesday. The company has a quick ratio of 1.40, a current ratio of 1.52 and a debt-to-equity ratio of 5.76. The company has a market capitalization of $62.94 billion, a PE ratio of 12.13, a PEG ratio of 0.54 and a beta of 1.30. Celgene has a 1-year low of $74.13 and a 1-year high of $137.45.

A number of hedge funds have recently modified their holdings of the stock. Ayalon Holdings Ltd. purchased a new stake in Celgene during the second quarter worth approximately $100,000. Atlantic Trust LLC purchased a new stake in Celgene during the second quarter worth approximately $101,000. Acropolis Investment Management LLC purchased a new stake in Celgene during the second quarter worth approximately $112,000. City Holding Co. purchased a new stake in Celgene during the second quarter worth approximately $143,000. Finally, Sun Life Financial INC grew its stake in Celgene by 528.9% during the second quarter. Sun Life Financial INC now owns 1,918 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 1,613 shares during the period. 73.11% of the stock is owned by hedge funds and other institutional investors.

In related news, Director Ernest Mario sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, August 9th. The shares were sold at an average price of $92.32, for a total transaction of $1,107,840.00. Following the completion of the transaction, the director now owns 44,413 shares of the company’s stock, valued at $4,100,208.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John H. Weiland purchased 5,575 shares of the company’s stock in a transaction that occurred on Tuesday, August 7th. The shares were bought at an average cost of $89.73 per share, with a total value of $500,244.75. The disclosure for this purchase can be found here. Corporate insiders own 0.39% of the company’s stock.

About Celgene

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Read More: What are the risks of holding treasury bonds?

Earnings History and Estimates for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.